文献速递前列腺癌

局限性前列腺癌治疗后的患者报告结局及其与治疗决策后悔的关联

Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices.
PubMed 文献 · Eur Urol Oncol · 2018-12-26

这项前瞻性、观察性、多中心研究纳入2014—2016年诊断的cT1-2期局限性前列腺癌男性434例(主动监测32%、根治性前列腺切除术45%、外照射放疗12%、近距离放疗10%),在治疗前及治疗后3、6、12个月完成患者报告结局量表。随访1年时,不同治疗方式对应不同的泌尿、性、激素/男性气质及情绪困扰模式;无论治疗方式如何,23%的患者报告有临床相关的治疗后悔(99%CI 17-28%)。

要点

  • 根治性前列腺切除术组较主动监测组报告更多尿失禁、性功能障碍、激素/男性气质相关症状及更少情绪困扰(p<0.01)。
  • 外照射放疗组较主动监测组报告更多性功能障碍、激素/男性气质相关症状及躯体困扰。
  • 近距离放疗组较主动监测组报告更多尿路梗阻和刺激症状;23%患者报告临床相关治疗后悔(99%CI 17-28%)。

核心结论

  • 治疗后的躯体和社会心理功能与特定治疗方式及治疗前功能显著相关。
  • 经历不希望的躯体、社会心理和肿瘤学结局的患者较频繁报告治疗后悔。
  • 应加大努力以了解对患者进行关于治疗可能后果和疗效的仔细教育是否有助于限制治疗后悔感。

研究设计与样本

  • 前瞻性、观察性、多中心研究,纳入2014—2016年诊断的cT1-2期局限性前列腺癌男性。
  • 分析队列共434例男性(主动监测32%、根治性前列腺切除术45%、外照射放疗12%、近距离放疗10%)。
  • 患者在治疗前及治疗后3、6、12个月完成经验证的患者报告结局量表(QLQ-C30、QLQ-PR25、决策后悔量表、Memorial前列腺癌焦虑量表)。
  • 采用混合效应模型描述不同的患者报告结局模式。

主要发现

  • 随访应答率超过90%。
  • 随访1年时,根治性前列腺切除术组较主动监测组报告显著更多的尿失禁、性功能障碍、激素/男性气质相关症状及更少的情绪困扰(p<0.01)。
  • 外照射放疗组较主动监测组报告更多的性功能障碍、激素/男性气质相关症状及躯体困扰。
  • 近距离放疗组较主动监测组报告更多的尿路梗阻和刺激症状。
  • 无论治疗方式如何,23%的患者报告有临床相关的治疗后悔(99%置信区间17-28%)。

关键数值与推荐

  • 决策后悔的多变量相关因素为激素/男性气质相关症状、教育水平和阳性手术切缘。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Well-documented reports of patients' experiences with different treatments are important for helping localised prostate cancer (LPC) patients choose among the available treatment options. OBJECTIVE: To document differences in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), and active surveillance (AS), and to evaluate how these PROs and other factors are associated with treatment decision regret. DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, multicentre study of men diagnosed with LPC (stage cT1-2) during 2014-2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients completed validated PRO measures (Quality of Life Questionnaire Core 30 [QLQ-C30], Quality of Life Questionnaire prostate cancer-specific module [QLQ-PR25], Decision Regret Scale, and the Memorial Anxiety Scale for Prostate Cancer) before treatment and at 3, 6, and 12mo after treatment. Mixed-effect models were used to describe different PRO patterns. RESULTS AND LIMITATIONS: The analytic cohort included 434 men (AS=32%; RP=45%; EBRT=12%; BT=10%). Follow-up response rates were above 90%. At 1-yr follow-up, (1) men who had received RP reported significantly (p<0.01) more urinary incontinence, sexual dysfunction, hormonal/masculinity-related symptoms, and less emotional distress; (2) those having received EBRT reported more sexual dysfunction, hormonal/masculinity-related symptoms, and physical distress; and (3) those having received BT reported more urinary obstruction and irritation symptoms, compared with patients under AS. Irrespective of the treatment modality, 23% of the patients reported clinically relevant treatment regret (99% confidence interval, 17-28%). Multivariate correlates of decision regret were hormonal/masculinity-related symptoms, educational level, and positive surgical margins. CONCLUSIONS: Post-treatment physical and psychosocial functioning was significantly associated with specific treatment modalities and pretreatment functioning. Regret was relatively frequently reported by patients who experienced unwanted physical, psychosocial, and oncological outcomes. Greater efforts should be made to understand whether carefully educating patients about the possible consequences and effectiveness of treatments may help limit the feeling of treatment regret. PATIENT SUMMARY: In men with localised prostate cancer, regret about the treatment choice was more common among those who experienced more treatment-related symptoms during the year after treatment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. van Stam MA, Aaronson NK, Bosch JLHR, et al. Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. Eur Urol Oncol. 2018. PMID: 31411965. doi:10.1016/j.euo.2018.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。